BMO Capital Downgrades Globus Medical to Market Perform, Cuts Target to $78
The firm cut its price target to $78 from $94, down from a prior median target of $99 across 13 firms covering the stock.
Key points
- BMO Capital cut its rating to market perform from outperform before the open on Nov. 6
- Price target cut to $78 from $94, versus a $99 median across 13 covering firms
- Globus Medical closed at $81.44 on Nov. 5, after an 11.1% rise over 20 sessions
- Cash and investments totaled $871.2 million as of Sept. 30
BMO Capital downgraded Globus Medical Inc (NYSE: GMED) to market perform from outperform before the open on Friday, Nov. 6, 2026, and cut its price target to $78 from $94.
The move leaves the stock with one firm acting in the session's coverage record.
Where coverage stands
Of the 13 firms that rated Globus Medical in the past year, 10 rated it positive and three rated it neutral before Friday. None rated it negative. Before the BMO action, the median target across those firms was $99, with a range of $80 to $123.
Price and filings
Globus Medical closed at $81.44 on Thursday, Nov. 5, 2026, after rising 11.1% over the prior 20 sessions. The company filed its quarterly report on Form 10-Q on Thursday, Nov. 5, one day before the action, according to its SEC filing index.
Company scale
For the 2025 fiscal year, Globus Medical reported revenue of $2.94 billion, up 17%, and diluted earnings per share of $3.92. In the latest reported quarter ended Sept. 30, 2026, revenue was $763.7 million, down 0.7% from a year earlier. The company had cash and investments of $871.2 million as of that date. Its market capitalization before the filing was about $10.79 billion.
Sources
Written with AI from analyst rating changes, SEC filings and market data, and checked against those sources before publishing. Our editorial standards.
More analyst ratings
- JPMorgan Upgrades Mercury Systems to Overweight, Cuts Target to $102 · MRCY · Nov. 11, 2026
- Keybanc Upgrades Maravai Lifesciences to Overweight, Sets $11.00 Target · MRVI · Nov. 12, 2026
- Five Analysts Downgrade Nvidia, Cut Targets at Three Firms · NVDA · Nov. 12, 2026
- Cantor Fitzgerald Initiates Academy Sports at Overweight; Loop Cuts to Hold · ASO · Nov. 10, 2026
More on Globus Medical
GMED page →Filings, figures and price history are on the Globus Medical page.